A population-based congenital cytomegalovirus screening program in Ontario successfully screened 551,034 newborns; of those ...

Chemical structure of valganciclovir hydrochloride. VLGH is a FDA approved medication for the prevention of CMV disease in certain transplant recipients at high risk for developing CMV diseases ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Viracta ...

In the NAVAL-1 trial, San Diego-based Viracta was testing nana-val, which is a combination of the investigational HDAC inhibitor nanatinostat and the anti-viral agent valganciclovir, as a treatment ...

We wanted to find out if pre-emptive treatment aimed at transplant recipients who are at risk of developing CMV disease, rather than administering universal prophylaxis, including those who are ...